Biogen (BIIB) Non Operating Income (2014 - 2022)
Biogen (BIIB) posted quarterly Non Operating Income of -$263.3 million for Q1 2022, up 48.06% year-over-year from -$177.8 million in Q1 2021, and down 44.59% quarter-over-quarter from -$182.1 million in Q4 2021.
Biogen (BIIB) Non Operating Income (2014 - 2022) Analysis & Trends
Biogen's Non Operating Income history runs 9 years deep, the most recent figure standing at -$263.3 million for Q1 2022.
- In Q1 2022, Non Operating Income rose 48.06% year-over-year to -$263.3 million; the TTM figure through Mar 2022 stood at -$851.9 million (down 867.48% YoY), while the FY2025 annual figure was -$305.6 million, up 11.06% from the prior year.
- Non Operating Income for Q1 2022 stood at -$263.3 million, down from -$182.1 million in the prior quarter.
- The five-year high for Non Operating Income was $683.5 million in Q4 2020, with the low at -$506.9 million in Q1 2021.
- The 5-year median for Non Operating Income is -$41.0 million (2018), against an average of -$45.1 million.
- The sharpest annual moves came in 2019 and 2020: Non Operating Income slumped 472.17% in 2019, then surged 1486.41% in 2020.
- Biogen's Non Operating Income stood at -$28.6 million in 2018, then sank by 72.38% to -$49.3 million in 2019, then soared by 1486.41% to $683.5 million in 2020, then sank by 126.64% to -$182.1 million in 2021, then slumped by 44.59% to -$263.3 million in 2022.
- Business Quant data shows BIIB's Non Operating Income at -$263.3 million in Q1 2022, -$182.1 million in Q4 2021, and -$502.9 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -73.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 387.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -263.30 Mn |
| Dec 31, 2021 | -182.10 Mn |
| Sep 30, 2021 | -502.90 Mn |
| Jun 30, 2021 | 96.40 Mn |
| Mar 31, 2021 | -506.90 Mn |
| Dec 31, 2020 | 683.50 Mn |
| Sep 30, 2020 | -128.60 Mn |
| Jun 30, 2020 | 63.00 Mn |
| Mar 31, 2020 | -120.50 Mn |
| Dec 31, 2019 | -49.30 Mn |
| Sep 30, 2019 | -27.30 Mn |
| Jun 30, 2019 | -197.40 Mn |
| Mar 31, 2019 | 357.30 Mn |
| Dec 31, 2018 | -28.60 Mn |
| Sep 30, 2018 | 115.10 Mn |
| Jun 30, 2018 | -34.50 Mn |
| Mar 31, 2018 | -41.00 Mn |
| Dec 31, 2017 | -66.40 Mn |
| Sep 30, 2017 | -44.00 Mn |
| Jun 30, 2017 | -68.60 Mn |